ClinicalTrials.gg
RecruitingNCT05753137Updated Jul 3, 2024

Acupuncture as Adjuvant Therapy for Glaucoma - Protocol for a Randomized Controlled Trial

An interventional study of Acupuncture and Acupuncture placebo in Glaucoma, Acupuncture and Intraocular Pressure, sponsored by China Medical University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by China Medical University Hospital · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Glaucoma with a site in Taiwan — 3 open to participants now, 3 under way, none of them phase 3. Glaucoma · Taiwan.

Started
2023
the only one that year
No phase
3 of 14
2 open now
Registered
10th of 14
by date
Lead sponsor
2 of 14
China Medical University Hospital

Among the 14 studies in Glaucoma with a site in Taiwan, this one is the only one that started in 2023, is one of 3 with no phase, and was the 10th registered.

Glaucoma

1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

3 of the 14 studies in Glaucoma with a site in Taiwan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Glaucoma with a site in Taiwan, or all of them as a file.
02

Study summary

This clinical trial used acupuncture as an adjunctive treatment for glaucoma patients. A randomized, controlled trial involving 50 subjects will be conducted and observed for 12 weeks to evaluate the clinical efficacy of acupuncture. This study aims to provide a reference for future clinical treatment guidelines.

Read the detailed description

This clinical trial utilized acupuncture as an adjunctive treatment for glaucoma patients. It is estimated a randomized clinical trial that 50 subjects will be enrolled and observed for 12 weeks to evaluate the clinical efficacy of acupuncture, providing a reference for future clinical treatment guidelines. Participants will be randomly divided into two groups: Ophthalmic Acupoint Treatment Group and Non-ophthalmological Acupoint Control Group. Participants in the treatment group will undergo acupuncture targeting ophthalmology-related acupuncture points, aiming to elicit the 'De Qi' sensation. Conversely, the control group will receive minimum acupuncture stimulation targeting non-ophthalmic acupuncture points without the intention of achieving the 'De Qi' sensation. Both groups will undergo acupuncture therapy once a week for a total of six sessions and will be observed for twelve weeks. On each visit, intraocular pressure, blood pressure, and heart rate will be assessed. Questionnaires of Glaucoma Symptom Scale (GSS) and The Glaucoma Quality of Life-15 (GQL-15) will be performed. The data of central corneal thickness, optical coherence tomography angiography, optical coherence tomography, visual field, and best-corrected visual acuity will be collected and analyzed before acupuncture and in the 12th week.

03

Conditions studied

  • Glaucoma
  • Acupuncture
  • Intraocular Pressure

Browse trials for

Keywords

  • Glaucoma
  • Acupuncture
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Primary open angle glaucoma diagnosed at least 3 months ago.
  2. Diagnosed with mild or moderate open angel glaucoma.
  3. Use 1 or 2 kinds of glaucoma drugs.
  4. Age ≥ 20 years old.
  5. Participants sign the and cooperate with the experimental procedures.

Exclusion criteria

Exclusion Criteria:

  1. Accept any ophthalmic laser or surgery within one year.
  2. High myopia.
  3. Use of any drugs that affect intraocular pressure.
  4. Visual acuity with correction lower than 0.2.
  5. Previous or existing uveitis or retinopathy.
  6. Unable to receive acupuncture treatment continuously or allergic to acupuncture needles.
  7. Pregnancy or breastfeeding.
  8. Refusal to sign the form.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Ophthalmic Acupoint Treatment Group

    Ophthalmic acupoint treatment group will receive a total of 6 courses of treatment, once a week, a total of six weeks, 20 minutes each time. Acupuncture points: Fengchi(GB20), Cuanzhu(BL2), Sibai(ST2), Taiyang(EX-HN5), Hegu(LI4), Taichong(LR3), a total of six acupoints.

    Other: Acupuncture

  • Placebo comparator
    Non-ophthalmological Acupoint Control Group

    Non-ophthalmological acupoint control group will receive a total of 6 courses of treatment, once a week, a total of six weeks, 20 minutes each time. Acupuncture points: Yinlingquan(SP9), Liangqiu (ST34),Xiajuxu(ST39), Yanglingquan (GB34), Shousanli(LI10), Sanyangluo(TE8), a total of six acupoints. The Non-ophthalmological acupoint control group points are not indicated for the treatment of ophthalmological related pathologies, and are not reported to improve ophthalmological function.

    Other: Acupuncture placebo

Interventions

  • OtherAcupuncture

    The treatment will take place once a week, over six weeks. The needles will placed in the body for 20 minutes. A total of 12 Needles(6 acupoints, bilaterally) will be used in each session.Participants in the treatment group will undergo acupuncture targeting ophthalmology-related acupuncture points, aiming to elicit the 'De Qi' sensation.

  • OtherAcupuncture placebo

    A total of 12 Needles(6 acupoints, bilaterally) will be used in each session. Acupuncture points are different from the experimental group.The control group will receive minimum acupuncture stimulation targeting non-ophthalmic acupuncture points without the intention of achieving the 'De Qi' sensation.

06

What researchers measure

Primary outcomes

  1. Intraocular pressure-pre-treatment

    Intraocular pressure (IOP) is the fluid pressure of the eye.TOPCON CT-80 Computerized Tonometer is used for measurement.The unit of value is mmHg.

    Time frame: Every weeks pre-acupuncture treatment up to six weeks.

  2. Intraocular pressure-after-treatment

    Intraocular pressure (IOP) is the fluid pressure of the eye.TOPCON CT-80 Computerized Tonometer is used for measurement.The unit of value is mmHg.

    Time frame: Every weeks 15 minutes after acupuncture treatment up to six weeks.

  3. Intraocular pressure-Change

    Intraocular pressure (IOP) is the fluid pressure of the eye. Tonometer is used for measurement.The unit of value is mmHg.

    Time frame: Change from baseline intraocular pressure at 12 weeks.

Secondary outcomes

  1. Optical coherence tomography-RNFL symmety

    The optic disk and the RNFL are the principal sites of apparent glaucomatous damage which precedes glaucomatous visual field alterations. RNFL symmety and Retinal nerve fiber layer (RNFL) thickness measurements obtained with Optical coherence tomography employs low-coherence interferometry.The unit of value is %.

    Time frame: Change from baseline RNFL symmety at 12 weeks.

  2. Optical coherence tomography-C/D ratio

    The optic disk and the RNFL are the principal sites of apparent glaucomatous damage which precedes glaucomatous visual field alterations. The cup/disc (C/D) ratio as a standardised method to evaluate the optic nerve obtained with Optical coherence tomography employs low-coherence interferometry.

    Time frame: Change from baseline C/D ratio at 12 weeks.

  3. Optical coherence tomography angiography-RPC density

    Optical coherence tomography angiography is a relatively new, non-invasive, dye-free imaging modality that provides a qualitative and quantitative assessment of the vasculature in the retina and optic nerve head. We use OCTA to complement visual field and OCT examinations to diagnose glaucoma, detect progression and evaluate the treatment of acupuncture. Using OCT angiograms, the RPC density was evaluated quantitatively. The unit of value is %.

    Time frame: Change from baseline RPC density at 6 weeks.

  4. Central corneal thickness

    To measure mean values of central corneal thickness (CCT) obtained by specular microscopy.

    Time frame: On the first and 12th week for baseline and follow up tracing.

  5. Glaucoma Symptom Scale

    The Glaucoma Symptom Scale (GSS) is a simple and brief glaucoma-specific questionnaire aimed at quantifying complaints and functional impairment in patients with glaucoma. We used 1998 version of the Glaucoma Symptom Scale (GSS; Lee et al., 1998) Questionnaire.The items include 10 ocular complaints, for each eye, a 5-level score is generated, ranging from 0 (complaint present and very bothersome) to 4 (complaint absent). This score is then transformed to a 0 to 100 scale, with 0 representing presence of a very bothersome problem and 100 representing absence of a problem.

    Time frame: On the first and 12th week for baseline and follow up tracing.

  6. Glaucoma Quality of Life - 15

    The GQL-15 questionnaire is composed of 15 items. A 5-point rating scale for the level of difficulty of each task totals a score from 0 to 75. A higher score signifies a poorer .

    Time frame: On the first and 12th week for baseline and follow up tracing.

  7. Blood pressure

    We measure the blood pressure of patient before and after acupuncture treatment .Both systolic and diastolic blood pressure will be measured.

    Time frame: we measure blood pressure every weeks before and after acupuncture treatment of totally six weeks, and first and 12th week for baseline and follow up tracing.

  8. Heart rate

    We measure the heart rate of patient before and after acupuncture treatment .

    Time frame: we measure heart rate every weeks before and after acupuncture treatment of totally six weeks, and first and 12th week for baseline and follow up tracing.

  9. Best corrected visual acuity

    Best possible vision a an eye can see with corrective lenses, measured in terms of Snellen lines.

    Time frame: Change from baseline best corrected visual acuity at 12 weeks.

  10. Visual field- mean deviation

    The visual field refers to the total area in which objects can be seen in the side (peripheral) vision as you focus your eyes on a central point. Visual field will measured with automated perimetry.The unit of value is dB.

    Time frame: Change from baseline visual field at 12 weeks.

  11. Visual field- visual field index

    The visual field refers to the total area in which objects can be seen in the side (peripheral) vision as you focus your eyes on a central point. Visual field will measured with automated perimetry. Visual field index intuitive presentation may underestimate the visual loss.

    Time frame: Change from baseline visual field at 12 weeks.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. Glaucoma. Lancet. 2017 Nov 11;390(10108):2183-2193. doi: 10.1016/S0140-6736(17)31469-1. Epub 2017 May 31. PubMed 28577860 ↗
  • Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996 May;80(5):389-93. doi: 10.1136/bjo.80.5.389. PubMed 8695555 ↗
  • Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci. 1997 Jan;38(1):83-91. PubMed 9008633 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Jun 2025, 23 months after the start.

Of 230 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 23 months is below that.

Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2023
First posted
Mar 3, 2023
StartActual
Jun 28, 2023
Primary completionEst.
Jun 27, 2025
CompletionEst.
Jun 27, 2025
Last update
Jul 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05753137
Responsible party
Sponsor
First posted
Mar 3, 2023
Start date
Jun 28, 2023
Primary completion
Jun 27, 2025 (estimated)
Completion
Jun 27, 2025 (estimated)
Last update
Jul 3, 2024

Study contacts

LEE YU-CHEN, Ph.D
Contact
d5167@mail.cmuh.org.tw
886-4-22052121 ext. 1670
LEE YU-CHEN, Ph.D
study director · China Medical University, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion